Sen. Tim Sheehy introduced legislation Tuesday that would create a dedicated pharmaceutical trade negotiator at the Office of the U.S. Trade Representative and give the federal government new tools to push back against foreign drug-pricing policies he says shift research costs onto American consumers.

What this means for you
MontanaMontana has no major pharmaceutical manufacturing base, so the bill's direct economic effect here is limited. The broader argument — that American consumers overpay for drugs subsidized abroad — applies to Montana patients and employers who provide health coverage. Whether the bill advances, and whether trade pressure actually changes foreign pricing, determines any practical effect.
LocalNo direct county- or city-level effect identified.
Watch nextNo committee referral or hearing date was confirmed at the time of publication; track the bill's progress through the Senate Finance Committee, which handles pharmaceutical trade matters.

The bill is called the Use Sovereignty to Reduce Rx Act, or USTRx Act. Sheehy was joined by Sens. Ted Budd of North Carolina and Dave McCormick of Pennsylvania; companion legislation has been introduced in the House by Rep. Jody Arrington of Texas.

"America leads the world in developing lifesaving medicines, but for too long, foreign governments have gamed the system with price controls that force hardworking Americans to pick up the tab for these drugs," Sheehy said in the release. "That's not free trade — it's freeloading."

The bill would direct USTR to establish the Chief Pharmaceutical Trade Negotiator position, publish an annual report to Congress on foreign drug-pricing practices, and submit a formal response plan to the relevant House and Senate committees. That plan could include opening an investigation under Title III of the Trade Act of 1974.

The release cites a recent USTR Special 301 report identifying Germany and Japan among the countries using pricing policies that suppress drug values below what the office characterizes as fair market value. On June 18, 2026, USTR opened a Section 301 investigation against Germany over pharmaceutical pricing — a proceeding that is separate from this legislation but that Sheehy's office points to as context for the bill.

The USTRx Act does not directly set drug prices in the United States or restrict what pharmaceutical companies can charge domestically. Its mechanism is trade policy: pressure on foreign governments through reporting, negotiation, and the threat of formal trade action.

The bill text is linked from the release, though the406.news was unable to confirm the full legislative language through a public congressional source by publication time. The procedural details above are drawn from the senator's release. The bill's status — whether it has been referred to committee or received a hearing date — was not confirmed.